Over 77% of all pancreatic cancer patients were shown to have KRAS mutations, 42% of colorectal cancer cases have KRAS mutations, and approximately 30% of Non-Small Cell Lung Cancer (NSCLC) cases have KRAS mutations (Hu et al., 2021; Reita et al., 2022; Vaughn et al., 2011; Prior et al., 2012). Here, KRAS is linked to colorectal cancer.